iPS Cells & Regenerative Medicine– category –
-
Takeda Exits Cell Therapy, Shifts Strategy to AI Drug Discovery with Additional 4,500 Job Cuts in Restructuring
BioSpace USA Overview Takeda Pharmaceutical Company is undergoing a major restructuring, including a complete exit from cell therapy, to navigate 'existential risks,' shifting its focus to 'frontier science' such as AI-driven drug discov... -
AATD Treatment Race Intensifies: Beam Therapeutics Plans Pivotal Cohort for Accelerated Approval of Base Editor BEAM-302
CRISPR Medicine News USA Overview The field of Alpha-1 Antitrypsin Deficiency (AATD) treatment is witnessing heightened competition, with five gene editing companies reporting new data and Sanofi introducing a non-edited recombinant prot... -
Cell-Free Advantage: Exosome-Biomaterial Platforms Offer Safer Treatment for Diabetic Skin Infections, But Clinical Translation Remains Complex
International Journal of Nanomedicine (論文) Global Overview A recent review explores exosome-biomaterial platforms as a promising, safer alternative to cell therapies for diabetic skin infections. These 'cell-free' approaches address sa... -
Prime Medicine’s Autologous Prime Editing Hematopoietic Stem Cell Therapy PM359 for p47phox-Deficient Chronic Granulomatous Disease Receives FDA RMAT Designation
BiopharmaWatch (Prime Medicine Press Release) USA Overview Prime Medicine announced its investigational autologous prime editing hematopoietic stem cell therapy, PM359, for the treatment of p47phox-deficient Chronic Granulomatous Disease... -
Prime Medicine Secures NZ Clinical Trial Clearance for Prime Editing Therapy PM577a in H1069Q-Mutated Wilson Disease, Initiating Global Phase 1/2 Study
GlobeNewswire (Prime Medicine Press Release) USA Overview Prime Medicine has announced the approval of its Clinical Trial Application (CTA) in New Zealand for PM577a, an investigational prime editing therapy for H1069Q-mutated Wilson dis... -
Engineered Exosomes Breach Blood-Brain Barrier, Unlocking New Vistas in Neuro-Oncology
MDPI (論文) Global Overview The blood-brain barrier (BBB) critically impedes drug delivery to the brain, posing a major challenge for treating central nervous system diseases, particularly brain tumors. Engineered exosomes are emerging a... -
CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells
University Hospitals USA Overview CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, sugge... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
CRISPR Medicine News Roundup: Sickle Cell CRISPR Drug Shows Potent Results in Young Children, Caribou’s Off-the-Shelf CAR-T Delivers Positive Phase 1 Data
CRISPR Medicine News USA Overview A CRISPR Medicine News summary article reports that the first approved CRISPR gene therapy for sickle cell disease demonstrated equally potent results in children as young as 5 years old. Additionally, C... -
Exosomes: Unlocking Nature’s Nanoparticles for Precision Medicine, Navigating Translational Hurdles
Frontiers (論文) Global Overview Exosome research is rapidly advancing, revealing substantial potential in drug delivery and regenerative medicine due to their inherent biocompatibility and targeting capabilities. However, clinical trans...
